• Oregon-based Kirkman Group is FDA-licensed and cGMP-certified
• The acquisition, part of Hemptown’s vertical integration strategy, will enable the company to make its immediate entry into the consumer packaged goods field
• The company has already acquired and planted 4.5 million hemp seeds in plots across three states
• Forecast high yields and the latest acquisition are expected to enable Hemptown USA to position itself as a leader in the rapidly expanding cannabinoid product market

Hemptown USA, a privately held company headquartered in Southern Oregon’s Emerald Triangle, is currently focusing on its rapid, vertically integrated growth within the lucrative cannabis industry. As a part of this strategy, the company announced the acquisition of assets comprising the FDA licensed, cGMP-certified operating nutraceutical business of the Kirkman Group (http://ibn.fm/GaNUI).

Based in Lake Oswego, Oregon, Kirkman Group has finalized a transaction with Hemptown USA that encompasses the company’s management team, formulations, production equipment, proprietary intellectual property and current sale channels, among others. Kirkman’s former owner and chairman, David Humphrey, will remain with Kirkman, offering guidance in a role that’s yet to be determined.

The Kirkman Group’s 25,000-square-foot nutraceutical facility is fully operational and comprised of innovative equipment and formulations aimed at facilitating precision dosage of cannabidiol (CBD) and cannabigerol (CBG) product formulations, including tinctures, gel caps, topical products and edibles.

For over 70 years, the company has been supplying world-class formulations for children with autism. Currently, Kirkman produces $6 million in annual revenue, and forecasts suggest growth in the future.

This acquisition enables the completion of Hemptown USA’s vertical integration plans. In addition, it facilitates the company’s immediate entry into the consumer packaged goods field.

To ensure its stability and growth in the future, Hemptown USA is positioning itself as one of the prominent CBG manufacturers in the U.S. CBG, a type of cannabinoid that’s less commonly produced than CBD, is often called the “mother of all cannabinoids.” It is a precursor to other cannabinoid compounds, and studies suggest that it has immense health benefits.

In the spring of 2019, Hemptown USA acquired 4.5 million rare hemp seeds. These have been divided three ways – one third went to Kentucky, another third was planted in Colorado and the final third (all CBG genetics) remained in Oregon. The seeds were planted in greenhouses to begin with, and, in mid-summer, they were taken outdoors and planted on over 1500 acres of land in the three states.

Based on its crop production efforts and the acquisition of the Kirkman Group production facility, Hemptown USA can fast track formulations, product development and subsequent distribution.

Hemptown USA is already recognized for growing some of the finest hemp plants in the world. Following a successful first-year yield, Hemptown USA is currently working to scale up operations and benefit from the growing global demand for high quality cannabinoid products.

Having farmland in three states, as well in-house extraction facilities, enables Hemptown USA to vertically integrate the consumer packaged goods sector with top-quality branded lines for the consumer market. All of these steps and strategic decisions are expected to enable Hemptown USA to capitalize on a market that’s forecast to reach $22 billion by 2020.

Check out http://ibn.fm/fTpMc for a brief video on recent developments.

For more information, visit the company’s website at www.HemptownUSA.com

• MustGrow recently announced a cannabis biopesticide research and development program, in partnership with the National Research Council Canada, focused on MustGrow’s patented natural biopesticide
• MustGrow is also partnering with Triangle Plant Sciences (“TPS”) to offer exclusive Canadian and global access to TPS’s TP-1000 for the cannabis industry – the first product in a suite of researched hydroponic technology offerings
• Brian Quigley, a former Altria Group senior executive with extensive regulatory prowess, was recently appointed to MustGrow’s board of directors

MustGrow Biologics Corp. (CSE: MGRO), an agricultural biotech company developing and commercializing a portfolio of natural biopesticides and biofertilizers for the cannabis industry, has a mountain of good news to share with its stakeholders. MustGrow recently issued a number of strategic press releases that illustrate the significance of the company’s signature, patented products and the potential impact they are expected to have on the cannabis industry.

In a July 11 news release, MustGrow announced that it has launched a biopesticide research and development program with the National Research Council Canada (“NRC”) (http://ibn.fm/0mRoY). The NRC and MustGrow are conducting a series of efficacy assessments of MustGrow’s patented biopesticide as a natural pre-plant, pre-pot soil treatment for soil-borne pests and diseases that affect cannabis production. MustGrow intends to seek Health Canada approval for its natural biopesticide for eventual use by Canada’s licensed cannabis producers.

MustGrow’s novel and proprietary solutions utilize organic components refined from mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests such as nematodes. The global economic impact of soil-borne nematodes is estimated at nearly $100 billion in lost crops per year. The American Phytopathological Society (http://ibn.fm/iE9cW), an international nonprofit scientific organization dedicated to the study and control of plant diseases, estimates that plant-pathogenic nematodes are responsible for 14 percent of crop losses worldwide.

Health Canada requires mandatory testing of cannabis for a litany of pesticides and their active ingredients to ensure that pesticide-tainted cannabis is not showing up in tested products (http://ibn.fm/GisCt). MustGrow’s pre-plant/pot soil treatment has already demonstrated control of many soil-borne diseases and pests that affect cannabis production, including Botrytis (gray mold), Fusarium, Pythium root rot, Rhizoctonia fungus, nematodes, Verticillium wilt, Phytophthora root rot and Sclerotinia.

MustGrow is also partnering with Triangle Plant Sciences (“TPS”), a division of Verdesian Life Sciences of Cary, North Carolina, to exclusively provide TPS’s TP-1000 to cannabis growers in Canada. TP-1000 is the first product in a suite of researched hydroponic technology offerings that improve nutrient utilization in support of early growth and optimal flowering, according to a news release (http://ibn.fm/Ni202). Through the partnership, MustGrow will first offer TP-1000 exclusively in Canada, followed by distribution in key registered markets around the globe.

“We are thrilled to enter into a partnership with Triangle Plant Sciences,” MustGrow Chief Operations Officer Colin Bletsky stated in the release. “The vision of TPS aligns perfectly to that of MustGrow, and we look forward to working hand-in-hand to offer the TPS suite of hydroponic products throughout Canada and, eventually, the world.”

The recent appointment of Brian Quigley to MustGrow’s board of directors is another impressive addition to the company’s growing slate of experienced industry insiders. Quigley, who brings over 20 years of regulatory expertise, brand building, marketing and operations experience with him, spent the last 16 years at Altria Group. Seven of those years were as president and CEO for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company.

“Brian brings extensive regulatory prowess, brand building and product innovation experience to MustGrow,” Corey Giasson, CEO of MustGrow, stated in a news release (http://ibn.fm/jbKgZ). “His richly developed relationships in international food conglomerates, Big Tobacco and the cannabis community will spark powerful initiatives in all of MustGrow’s agriculture programs.”

MustGrow recently received Canadian Securities Exchange (CSE) approval for the listing of its common shares. The shares began trading on the CSE under ticker symbol ‘MGRO’ on July 10, 2019 (http://ibn.fm/LwQZh).

For more information, visit the company’s website at www.MustGrow.ca

NOTE TO INVESTORS: The latest news and updates relating to MGRO are available in the company’s newsroom at http://ibn.fm/MGRO

• TGOD is dedicated to high standards in the midst of a growing cannabis supply gap
• The company is increasing production rates and margins through its alliance with Eaton Corp. and its use of high-tech hybrid facilities
• TGOD is creating a positive economic impact in local towns across Canada

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) produces farm-grown, premium, certified-organic medical cannabis in small batches in Hamilton, Ontario, and Valleyfield, Quebec. Even in the midst of an expanding supply gap, TGOD’s officials know that time spent cultivating product through clean, natural and sustainable methods is worth the wait, and attention to detail leads to an outstanding product that meets the highest standards for organic cultivation. Dedication to that knowledge shows in every step of the company’s production process.

TGOD is one of three organic cannabis growers in Canada. No synthetic pesticides or fertilizers are used in the company’s growing process. The company is also dedicated to creating a smaller environmental footprint by using less water and energy, low-cost power solutions and smarter efficient packaging. By growing organically and at low costs, TGOD’s final product demands a premium in the market, thereby increasing margins.

In April, Marijuana Business Daily reported that Canadian cannabis wholesalers are reporting a CBD shortage (http://ibn.fm/CaGzx). The demand for product has been higher than expected, and companies such as TGOD are working to ensure that the gap is filled, without sacrificing on quality standards. Certified organic by North America’s most-recognized organic certification bodies – Pro-Cert and ECOCERT Canada – TGOD stands by the slower, more sustainable methods of growing, believing them to be the best way to provide consumers with the premium products they deserve.

To fill the gap without sacrificing quality, TGOD is pursuing the construction of enclosed, high-tech hybrid facilities for cannabis growth designed to increase its production rate by 100 times. TGOD’s Hamilton Facility is nearing completion of a 139,000-square-foot, state-of-the-art hybrid greenhouse, with the first harvest anticipated at the end of Q3 2019. In January 2018, TGOD broke ground on its Valleyfield Facility, set to be the world’s largest organic cannabis facility. Plans call for a 1.31 million square-foot, high-tech facility capable of producing 185,000 kg of premium organic cannabis annually. The first cultivation from this facility is slated for Q4 2019. The property is dual zoned, allowing for cultivation, research and development and product manufacturing to all take place in one location (http://ibn.fm/trY7y).

As TGOD expands its footprint into international markets and pursues its goal of becoming a global leader in the distribution of organic cannabis, the company is also committed to creating a positive economic impact in local towns across Canada. TGOD takes care of the earth it uses and the communities in which it works. In addition to cannabis, the company maintains a community farm that produces fresh organic food for the local Hamilton food-share programs to help feed the hungry. The community farm donated more than 6,000 pounds of food in 2018.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• The team at Covered Bridge Acres employs environmentally friendly practices; it’s in the process of obtaining organic certification
• The MCOA and GHG teams utilize greenhouses to produce their own seeds instead of purchasing cloned product from third parties
• This strategic change is forecast to reduce the company’s operating expenses by $200,000

Marijuana Company of America Inc. (OTCQB: MCOA), an industrial hemp company involved in the cultivation and distribution of hemp-derived products, along with joint venture partner Global Hemp Group (CSE: GHG) (OTC: GBHPF) (FRA: GHG), recently announced the commencement of commercial planting at its hemp farm in Scio, Oregon.

This high-yielding, CBD-hemp farming project between partner companies has been eagerly anticipated since its announcement in 2018. Work to prepare 35 acres of land at the farm, which operates under the name Covered Bridge Acres Ltd. (“CBA”), has been completed, and the process of laying the last of the mulch and drip line is being finished. The farm is also in the process of obtaining organic certification (http://ibn.fm/yMMIr). Among other strategies to engage environmentally friendly practices, farm officials brought in biodegradable plastic from Canada to eliminate end-of-season environmental waste and reduce labor costs associated with its removal from the field.

The team at Covered Bridge Acres has taken steps to increase crop stability and quality this season while also reducing expenses. In lieu of purchasing cloned plants or seeds from other companies, as in prior seasons, the hemp plants used for this year’s cultivation have been produced from either sprouted seed or through CBA’s cloning operation conducted onsite at the company’s greenhouses and under full control of the CBA team.

Additionally, this year’s crops used superior genetics with increased stability when compared to those in prior years. The team expects to plant 40,000 to 50,000 plantlets this year, with a CBD content ranging from 12 to 15 percent. Excess clones will be sold or used for expansion. Eliminating the need to purchase clones from third parties by utilizing the farm’s greenhouses for production is expected to reduce operating expenses in the current year by approximately $200,000.

The team at Covered Bridge Acres continues preparing its greenhouses for constant harvest to produce high-quality, smokable hemp flower. Trimmed, high-end flower with less than 0.3 percent THC currently wholesales for 10-times the price of CBD biomass going to extraction.

Marijuana Company of America has roots in the cannabis industry dating back to 2009. MCOA CEO Don Steinberg founded the first marijuana company to trade on a U.S. stock market, Medical Marijuana Inc. He and his partner, Charlie Larsen, have witnessed the evolution of the industry through legalization shifts and the emergence of hemp-based CBD products.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• CIIX is a leading financial information provider for Chinese-speaking investors
• The company’s emphasis is on providing dependable market information to assist investors in making wise investment decisions
• CIIX is leveraging initiatives in the cryptocurrency space

ChineseInvestors.com Inc. (OTCQB: CIIX) is a foremost financial information website for Chinese-speaking investors in the United States, China, Canada and worldwide. The company has operated the premier web portal for more than 20 years. Through its website, CIIX provides real-time market commentary and analysis, as well as education-related services in both traditional and simplified Chinese language character sets (http://ibn.fm/EBG1O). Established in 1999, CIIX is based in San Gabriel, California, and also has offices in Flushing, New York, and Shanghai, China.

CIIX’s focus is on providing reliable market information to assist investors in making knowledgeable investment decisions and meeting their individualized financial objectives. Its subscriber base, which consists of both free and paid members, is primarily located in the United States and Canada. The company’s services are typically delivered to U.S. public and private companies and U.S. residents and citizens (http://ibn.fm/UAJsx). In addition, CIIX offers consultative services to smaller private companies that are considering going public and provides advertising and public relations-related support services.

CIIX features its proprietary ChineseInvestors Method, an inventive integration of a disciplined investing process, web-based tools, personalized instructions and support. With this strategy, the company offers useful and timely market data, tracks U.S. stock market quotes and provides access to sample investment portfolios for educational purposes and real-time trading demonstrations.

The website offers two membership levels: U.S. Stock Card Member and Regal Supreme Member. For its members, the ChineseInvestors.com website provides the following:

• “Must Buy Classics,” a live U.S. stock broadcast;
• “Profitable Hotspots,” the first gold for retail investors;
• “Can’t Help but Watch” regarding pptions & bitcoin VIP live;
• “Investment Must-See,” CIIX’s U.S. stock college curriculum; and
• “Long-Term Essentials” dealing with value growth stocks each month.

CIIX is committed to staying up to date on new developments in the cryptocurrency space. The company has expanded its lineup to include a number of cryptocurrency products (http://ibn.fm/08AwU), including www.NewCoins168.com. This free site provides news and investment education in the Chinese language and covers cryptocurrency basics, trading guidelines, market commentary and analysis concerning cryptocurrency, blockchain technology and mining. The website also covers other opportunities for subscribers to benefit from the cryptocurrency market.

CIIX also has Bitcoin Trading Academy LLC, its wholly owned subsidiary that launched in 2018. Headquartered on Wall Street in New York City, Bitcoin Trading Academy focuses on cryptocurrency trading and education in the blockchain technology arena (http://ibn.fm/7hHeb).

Through Bitcoin Trading Academy, CIIX creates daily video content for its Chinese-speaking market at www.BTA168.io. Academy services are available globally online and in-person through live events in select cities throughout the United States and Asia. Its educational series consists of Bitcoin Trading 101, 201 and 301. The purpose of this series is to provide students with the knowledge and practical experience necessary to trade successfully and with confidence (http://ibn.fm/yTXCa).

ChineseInvestors.com offers investors the potential for return on investment as it executes initiatives to grow its subscriber base. Moreover, the company has profited over the years from earning and holding shares in publicly traded companies via its consulting and advisory services. CIIX continues to emphasize offering first-rate information to its stable, subscriber-based IR business, which has allowed the company to invest in other sectors.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• While the post-operative pain management market is anticipated to grow, the U.S. is looking for alternatives to traditional opioid administration
• Endonovo has alternative technologies that allow for effective pain and swelling management, bringing down the need for the administration of opioids
• Endonovo announced the rollout of its therapeutic device in hospitals and pain management centers across the U.S.; it’s planning to be in the evaluation stage with 600 hospitals over the course of 18 months

The global post-operative pain management market is anticipated to grow at a CAGR of 5.4 percent through 2023, with an increasing number of surgeries worldwide and a growing prevalence of different diseases as major factors for the growth of the market, according to a Market Research Future report (http://ibn.fm/iyZIR). An increasing aging population around the globe will also has a considerable impact on the growth of the market, the report underlines.

Apart from expanding, this market is also rapidly evolving. Researchers are currently working on effective pain management solutions with minimal side effects, amid growing concerns over the high number of pain management drug overdoses. Some reports even suggest that the opioid crisis in the U.S. is the result of inappropriate pain management after surgery (http://ibn.fm/WZCks).

The federal government has provided more than $2.4 billion in grants since 2017 to stimulate the development of alternatives for pain management in an attempt to reduce the scope of opioid addiction.

Endonovo Therapeutics Inc. (OTCQB: ENDV) is delivering a safe and reliable alternative to opioid medications for the management of pain.

Endonovo offers safe, wearable and non-invasive medical devices that deliver the company’s proprietary Electroceutical(TM) Therapy. The Endonovo SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. Clinical research suggests that it can speed up the recovery process and reduce the need for administration of potentially addictive opioids.

Peer-reviewed clinical research shows that patients who are offered targeted pulsed electromagnetic field therapy (the patented therapeutic mode employed by SofPulse) experience reduced post-surgical pain. The need for the administration of narcotics is reduced 2.2 times and the patients benefit from improved wound healing, reduced inflammation and edema.

SofPulse was recently rolled out in hospitals, nursing centers and wound care centers throughout the U.S. as an effective post-surgical opioid alternative. As per an official Endonovo announcement, the company plans to be in the evaluation stage with 600 hospitals within the coming 18 months (http://ibn.fm/7L5G6). In addition, Endonovo will distribute SofPulse therapy devices to Veterans Administration facilities and Department of Defense health care facilities.

“The public is demanding change in pain management strategies, especially when it comes to opioid administration”, Endonovo CEO Alan Collier said in a news release. “Very few alternatives exist at the time being, which allows SofPulse to position itself as a natural and safe alternative.”

Endonovo’s SofPulse has U.S. Federal Drug Administration (FDA) clearance for the treatment of post-surgical pain and edema. SofPulse is also CE-marked in Europe for the promotion of wound health and the palliative treatment of post-surgical pain and edema.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• SinglePoint has signed a contract to become the exclusive solar marketing partner and donate funds to 47 schools
• The company also inked a premium hemp-flower deal
• SING offers investment opportunity across a wide range of market sectors

Direct Solar, a subsidiary of SinglePoint Inc. (OTCQB: SING), recently announced that it has signed a contract to become the exclusive solar marketing partner to support fall sports programs for 47 schools across the Dallas/Fort Worth, Houston, Austin and Waco areas. According to the contract, the company will donate $250 to the schools’ fall sport booster programs for each solar system sold by the company within these school districts from August 1 to December 31, 2019.

“We hope that this promotion will be a great success,” Direct Solar founder and CEO Pablo Diaz said in a news release (http://ibn.fm/7hc81). “Nothing would make me happier than to cut some very large checks at the end of the year to support these schools and their sports programs.”

In addition, on June 27, 2019, SinglePoint Inc. announced that it had signed a contract to supply more than 275,000 pounds of premium hemp flower over a period of 15 months.

“There is very little high-quality hemp flower in the United States, so we’re pleased that our client can take advantage of our supply before it’s available to other supermarket clients,” SinglePoint President Wil Ralston stated in a news release (http://ibn.fm/pFXrb). “After visiting with our suppliers, it is clear that the market is drying up quickly, and we have access to supply the best flower available to the market with additional greenhouse quality flower coming to market as well.”

SinglePoint is a publicly traded holding company based in Phoenix, Arizona, specializing in acquisitions of small to mid-sized firms, with an emphasis on new technologies. The company provides investors the opportunity to make investments across a wide range of market sectors, including payment processing, cannabis and blockchain technologies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint’s corporate presentation is available at http://ibn.fm/xh6oE

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• Supreme is building a diverse portfolio of domestic and global premium cannabis brands
• The company is revolutionizing strain development for the global cannabis market
• Supreme delivers consistently premium products and investment opportunities through its wholly owned subsidiaries and partnerships

Canada’s only coast-to-coast premium cannabis producer, The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), is passionate about its products. The company provides high-quality brands and products that elevate its mission of becoming a leader in the global cannabis industry. Rather than focus on simply upping production, Supreme Cannabis pursues the production of the best cannabis possible, aiming for sustainable quality and superb craftsmanship. Consumers have come to expect the best from Supreme Cannabis brands, resulting in a loyal customer base for the company that continues to expand globally.

Supreme Cannabis has effectively built a diversified portfolio of successful cannabis brands. These brands include 7ACRES, Cambium Plant Sciences, Supreme Heights, KKE and Medigrow Lesotho. The company is expanding both domestically and internationally.

7ACRES operates from a 440,000-square-foot cultivation facility in Kincardine, Ontario. The facility’s annual capacity for dried cannabis is projected to reach approximately 50,000 kilograms per year following the licensing of all 25 flowering rooms. In May, 7ACRES obtained Health Canada approval for five additional flowering rooms, a move that means an increase from 180,000 square feet and an estimated annual capacity of 26,250 kilograms to 230,000 square feet and 33,580 kilograms.

“The finish line is in sight,” Supreme Cannabis president and founder John Fowler said in a news release. “As 7ACRES continues to work toward full production capacity, we are excited to fulfill demand for our high-end cannabis from enthusiasts coast to coast.”

The cannabis industry has taken notice of 7ACRES’ ability to cultivate high-end cannabis at scale, and a demand for the company’s proprietary genetics and cultivation techniques birthed the launch of Cambium Plant Sciences.

“It was as a result of the demand that we saw a global opportunity to create a company whose sole focus is innovating plant genetics and cultivation IP for the global cannabis market,” added Supreme Cannabis CEO Navdeep Dhaliwal. “Cambium will develop cultivars that benefit our in-house brands as well as our domestic and global cultivation and manufacturing partners.”

This wholly owned subsidiary aims to lead the agricultural revolution of cannabis genetics, redefining consumer experiences and cultivation economics across the global cannabis industry (http://ibn.fm/zOSvh). Cambium will aim to provide disease-resistant, premium seed to the ever-increasing, agriculturally focused global cannabis market and establish itself as a leading player in revolutionizing strain development.

Supreme Heights is a separate entity based in London. This CBD-focused investment platform is tapping into the quickly developing premium-CBD health and wellness sector in the United Kingdom and across Europe. Supreme provides capital and guidance to help early-stage entrepreneurial firms. The company seeks to support businesses that embrace sustainability, innovation and community throughout the UK and Europe.

Khalifa Kush Enterprises (KKE) is an international partnership aimed at developing and launching a line of premium cannabis-oil products. The oils are created using 7ACRES’ high-end cannabis and are among the first-ever recreational-focused cannabis oils in Canada. KKE Oils are available in British Columbia, Alberta and Ontario, and are scheduled to be released to other Canadian provinces throughout the year.

Medigrow Lesotho is the company’s international medical cannabis oil producer in Southern Africa. South Africa’s Department of Health recently made changes that allowed for the legal sale of CBD products that meet the government’s specified preparations, creating more opportunity for Medigrow to manufacture and supply high-quality CBD oil to its neighboring jurisdiction. In anticipation of its first international exports, Medigrow is creating an inventory of oils.

Supreme’s business model also includes key industry agreements to facilitate an active growth plan, a continued commitment to identifying new opportunities to grow its portfolio on a global scale and additional partnerships with cannabis retailers to further distribution. The company is focused on growing both domestically and internationally.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Pareteum is building on sales and acquisition successes by joining the Russell 3000 Index, granting the company a higher investment profile
• Pareteum’s cloud platform and related services connect millions of people in dozens of countries over numerous networks, with most of the company’s revenues currently coming from Europe
• The SaaS market is expected to expand at a CAGR of 21.2 percent through 2023, and the overall cloud market is expected to grow by 17.3 percent this year, showcasing the rising demand for related products and services
• The company’s second quarter financial report, anticipated next month, is expected to show the company beating analysts’ forecasts for revenue and EBITDA

Communications cloud services provider Pareteum Corp. (NASDAQ: TEUM) established its chops as a growing software as a service (SaaS) enterprise when it joined the Russell 3000 Index earlier this month following the Russell U.S. Indexes’ annual reconstitution. The reconstitution captures the 4,000 largest U.S. stocks each year, and Russell indexes are actively consulted by investment managers and institutional investors. The indexes are used as benchmarks for active investment strategies, according to a news release about the company’s activities (http://ibn.fm/WQ0es).

“We are executing on our growth strategy and we believe inclusion in the index is a testament to the strong performance we have achieved,” Pareteum Chairman and CEO Hal Turner stated in a news release, adding that the index “raises Pareteum’s profile among the investment community, may initiate increased institutional ownership of our stock, and is another step toward our commitment to generating long-term shareholder value.”

Pareteum’s Global Cloud Communications Platform connects millions of people and devices in Europe and other countries, and the company has its eye set on the opportunities posed by the estimated 30 billion devices that will need to be connected and managed through service providers, brand marketing firms and enterprise and Internet of Things (IoT) providers. The company’s recent acquisitions of software platforms Artilium and iPass grant it access to 59 mobile networks in 80 countries that use varied communications channels. Those channels are integrated and turned into value-added services for customers and app developers, according to the company (http://ibn.fm/JnCjS).

The principal part of the platform is Pareteum’s self-developed software and intellectual property. The company has about 40 patents covering its techniques and processes for its cloud software and communications platform product. HPE, IBM, Sonus, Oracle, Microsoft, NetNumber and Affirmed are listed among the company’s services partners.

SaaS partnerships are becoming an integral part of how companies worldwide do business. According to a report by Business Wire, quoted in a Customer Guru industry assessment, 2018 was a poster year for SaaS organizations as a whole, because the year saw several high-growth SaaS companies go public (http://ibn.fm/PXdls). The report states that the SaaS market is expected to rise at a compound annual growth rate (CAGR) of 21.2 percent between 2018 and 2023.

The report further adds, “We believe that the cloud market is a precursor to the overall SaaS market because cloud is the platform that makes SaaS a reality.” It notes that market research and advisory firm Gartner Inc. predicts that the overall cloud market will grow by 17.3 percent in 2019 and that the cloud system infrastructure services segment will grow by 27.6 percent this year.

Pareteum announced July 1 that its positive preliminary financial results for the second quarter of 2019 show it exceeding analysts’ consensus of $26.2 million for revenue and $4.1 million for adjusted earnings before interest, tax, depreciation and amortization (EBITDA). The official final publication of the company’s quarterly performance will take place August 6, along with a conference call to discuss the results, but, for now, the company states (http://ibn.fm/2IBvB) that the results “represent significant ongoing revenue growth and bottom-line improvement for the company.”

The company’s first quarter report showed a year-over-year growth rate of 460 percent and an adjusted EBITDA increase of 1,723 percent to $5.2 million (http://ibn.fm/eyKK5).

For more information, visit the company’s website at www.Pareteum.com

• Trxade Group is using the strength of its web-based purchasing platform, pharmacy network, delivery services and data analytics to improve the transparency of the prescription drug industry supply chain
• The company is celebrating a boost to its own transparency efforts with the news that the SEC approved its S-1 Registration Statement regarding shareholder stock resale
• Trxade Group reported record revenues of $1.5 million for the quarter ended March 31, as well as increasing operating income and net income
• The company’s software trading platform lists nearly half of the United States’ 24,000 independent pharmacies as subscribers, with ongoing additions to the platform

Pharmaceutical services company Trxade Group Inc. (OTCQB: TRXD) recently announced the Securities and Exchange Commission’s approval of its S-1 Registration Statement regarding the occasional resale of the company’s stock by its shareholders — part of Trxade Group’s efforts to comply with SEC filing standards.

“We have been working diligently on our registration statement since April 2019, and we are extremely delighted to announce that the SEC has informed the company that its S-1 Registration Statement is now effective. The S-1 Registration Statement lays the groundwork for transparency, oversight and financing program,” CEO Suren Ajjarapu stated in a news release (http://ibn.fm/5TBmq).

Trxade is building a reputation as “the trusted pharmaceutical marketplace” in an effort to provide the more than 10,500 independent pharmacies that subscribe to its software trading platform with competitive drug pricing options and reduced product shortages while working reliably within U.S. pharmaceutical distribution channels and without production modification.

Its services include its Internet-based purchasing platform, E-Hub-linked pharmacist network and consumer drug delivery services. Trxade also offers pharmacies predictive data analytics features and same-day delivery options to help manage availability concerns.

The company’s first quarter financial results showed record quarterly revenues of $1.512 million, as well as a record number of subscribers, an increase in operating income and increasing net income (http://ibn.fm/8ungO).

Drug development remains a prime mover in the biopharmaceutical industry as companies continue to raise unprecedented amounts of capital while advancing toward Food and Drug Administration (FDA) approval for promising new therapies to supply an increasingly health-conscious society searching for solutions to maintain rewarding lifestyles. Health care investment advisers at Edgemont Partners note that combined public and private market funding for pharmaceutical companies, mostly for drug development, has exceeded $100 billion annually since 2015 but was less than $40 billion per year prior to that (http://ibn.fm/ey8wa).

New and upcoming drug options also raise concerns about how consumers can obtain the most affordable products, especially amid news of astronomical generic drug price increases fueling a recently filed price-fixing lawsuit (http://ibn.fm/0I81V). Trxade’s services help independent pharmacies negotiate directly with drug makers without becoming dependent on the services of brokering third-party pharmacy benefit manager companies (PBMs) that may also harm independent pharmacies with their own opaquely administered fees (http://ibn.fm/eSITP).

“Trxade’s business focus is to become a leader in the PharmacyTech industry to meet the growing demand for supply chain and drug prices transparency technologies,” the company’s news release states.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD